279 related articles for article (PubMed ID: 26061438)
1. Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
Tolk H; Satzger I; Mohr P; Zimmer L; Weide B; Schäd S; Gutzmer R
Melanoma Res; 2015 Aug; 25(4):362-6. PubMed ID: 26061438
[TBL] [Abstract][Full Text] [Related]
2. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
3. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
4. BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
Desvignes C; Abi Rached H; Templier C; Drumez E; Lepesant P; Desmedt E; Mortier L
Melanoma Res; 2017 Jun; 27(3):281-287. PubMed ID: 28240681
[TBL] [Abstract][Full Text] [Related]
5. Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?
Bédouelle E; Nguyen JM; Varey E; Khammari A; Dreno B
Dermatology; 2022; 238(3):517-526. PubMed ID: 34818219
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.
Vanhaecke C; Deilhes F; Chanal J; Regnier-Rosencher E; Boitier F; Boulinguez S; Avril MF; Guégan S; Dupin N; Aractingi S; Meyer N; Kramkimel N
Br J Dermatol; 2017 Oct; 177(4):e94-e95. PubMed ID: 28129668
[No Abstract] [Full Text] [Related]
7. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
9. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
[TBL] [Abstract][Full Text] [Related]
10. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
[TBL] [Abstract][Full Text] [Related]
11. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
12. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
13. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
14. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
15. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
Finon A; Zaragoza J; Maillard H; Beneton N; Bens G; Samimi M; Caille A; Machet L
Eur J Dermatol; 2018 Feb; 28(1):38-43. PubMed ID: 29336315
[TBL] [Abstract][Full Text] [Related]
16. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
17. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
18. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
20. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.
Ponti G; Pellacani G; Tomasi A; Gelsomino F; Spallanzani A; Depenni R; Al Jalbout S; Simi L; Garagnani L; Borsari S; Conti A; Ruini C; Fontana A; Luppi G
J Clin Pathol; 2013 May; 66(5):441-5. PubMed ID: 23463675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
